ITGAM and neoplasm: Accordingly, the proportion of neutrophils (CD11b+Ly6G+F4/80− cells) fell in the spleen of mice that harboured responsive MI6 tumours and were treated with trastuzumab compared with untreated animals (Fig. 5c and Figure S7), supporting the use of this marker as an indicator of trastuzumab activity.